Principles of Cancer Therapy

Published on 10/03/2015 by admin

Filed under Obstetrics & Gynecology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1119 times

Chapter 37 Principles of Cancer Therapy

The standard modalities for the management of gynecologic cancer are surgery, chemotherapy, radiation therapy, and hormonal therapy. In this chapter, the principles of chemotherapy, radiation therapy, and hormonal manipulation are discussed, together with the principles of pain management and end-of-life issues. Targeted therapies and hyperthermia are at present experimental modalities and are not included.

image Cellular Biology

The characteristic feature of malignant tumor growth is its uncontrolled cellular proliferation, which requires replication of DNA. There are two distinct phases in the life cycle of all cells: mitosis (M phase), during which cellular division occurs; and interphase, the interval between successive mitoses.

Interphase is subdivided into three separate phases (Figure 37-1). Immediately following mitosis is the G1 phase, which is of variable duration and is characterized by a diploid content of DNA. DNA synthesis is absent, but RNA and protein synthesis occur. During the shorter S phase, the entire DNA content is duplicated. This is followed by the G2 phase, which is characterized by a tetraploid DNA content and by continuing RNA and protein synthesis in preparation for cell division. When mitosis occurs, a duplicate set of chromosomal DNA is inherited by each daughter cell, thus restoring the diploid DNA content. Following mitosis, some cells leave the cycle temporarily or permanently and enter the G0 or resting phase.

The growth fraction of the tumor is the proportion of actively dividing cells. The higher the growth fraction, the fewer the number of cells in the G0 phase and the faster the tumor-doubling time.

Chemotherapeutic agents and radiation kill cells by first-order kinetics, which means that a constant proportion of cells is killed for a given dosage, regardless of the number of cells present. Both therapeutic modalities are most effective against actively dividing cells because cells in the resting (G0) phase are better able to repair sublethal damage. Unfortunately, both therapeutic modalities also suppress rapidly dividing normal cells, such as those in the gastrointestinal mucosa, bone marrow, and hair follicles.

image Chemotherapy

One of the major advances in medicine since the 1950s has been the successful treatment of certain disseminated malignancies, including choriocarcinoma and germ cell ovarian tumors, with chemotherapy.

CHEMOTHERAPEUTIC AGENTS

The common agents used in the management of gynecologic malignancies may be classified as shown in Table 37-1. This table also contains a summary of the main indications for and side effects of these drugs.

image Radiation Therapy

Radiation may be defined as the propagation of energy through space or matter.

BIOLOGIC CONSIDERATIONS

Time-Dose Fractionation of Radiation

Successful radiation therapy requires a delicate balance between dosage to the tumor and that to the surrounding normal tissues. A dose of radiation that is too high sterilizes the tumor but results in an unacceptably high complication rate because of the destruction of normal tissues.

Most normal tissues, such as gastrointestinal mucosa and bone marrow, have a remarkable capacity to recover from radiation damage by the division of stem cells as well as by repair of sublethal radiation damage. Tumors, in general, have less ability to repair and repopulate. This difference can be exploited by administering the radiation in multiple fractions, thereby allowing some recovery, particularly of normal cells, between fractions.

If the interval between each fraction increases, the total dose must increase to produce the same biologic effect because of the amount of recovery that will occur in the interval. Cells that survive the acute effects of radiation usually repair sublethal damage within 24 hours; therefore, conventionally fractioned radiation is usually given in daily increments.

When treating the pelvis with external radiation, each fraction is usually 180 to 200 cGy. In treating the whole abdomen, fractions are decreased to 100 to 120 cGy because the tolerance of normal tissues decreases as the volume irradiated increases. The major factors influencing the outcome of radiation therapy are summarized in Box 37-1.

MODALITIES OF RADIATION THERAPY

The modalities used to deliver radiation therapy are listed in Box 37-2. In general, there are two radiation techniques: teletherapy and brachytherapy. In teletherapy, a device quite removed from the patient is used, as with external-beam techniques. Figure 37-2 is a linear accelerator used to deliver external-beam pelvic radiation. In brachytherapy, the radiation source is placed either within or close to the target tissue, as with intracavitary and interstitial techniques. In contrast to external-beam therapy, intracavitary and interstitial techniques allow a high dose of radiation to be delivered to the tumor, whereas dosages to surrounding normal tissues are considerably lower and are determined by the inverse square law.

Teletherapy

Brachytherapy

INTRACAVITARY RADIATION

Intracavitary therapy is used particularly in the treatment of cervical and vaginal cancer. All applicators now in use should be afterloaded, which means that they are placed in the patient and their position checked by radiography before the radioactive substance is loaded into the applicator. Traditionally, brachytherapy has been given at a low dose rate using radioactive substances such as cesium-137 (137Cs). Applicators for the management of cervical cancer are placed under general anesthesia. For low–dose-rate therapy, the applicators are left in situ for 48 to 72 hours. Remote afterloading devices, such as the Selectron, allow the radioactive sources to be removed from the applicators when medical or nursing personnel enter the room, thereby significantly limiting staff exposure to radiation. More recently, high–dose-rate brachytherapy has been given, using radioactive sources such as iridium (192Ir) (Figures 37-3 and 37-4). Treatment is given as an outpatient, which is much more acceptable for patients.

Radioactive colloids, such as chromic phosphate (32P), may be instilled directly into the peritoneal cavity to treat minimal residual disease, particularly in patients with ovarian cancer. To be effective, these agents must achieve a uniform distribution throughout the cavity, which is difficult to achieve, so such agents are rarely used at present. 32P is a pure β (electron) emitter.

COMPLICATIONS ASSOCIATED WITH RADIATION

The success of radiation therapy depends on an exploitable gradient of susceptibility to injury in favor of normal tissue. Unfortunately, most malignant tumors are only marginally more sensitive to radiation than are normal tissues, so the total dose that can be delivered, and therefore the radiocurability, is limited by the associated complications.

image Hormonal Therapy

The estrogen receptor (ER) status of primary and metastatic breast cancer has been shown to be of therapeutic and prognostic significance. The ER and progesterone receptor (PR) status of endometrial cancer also have prognostic and therapeutic significance.

image Pain Management

More than 70% of patients with cancer develop significant pain at some point in their disease. Proper pain management requires an understanding of pain physiology, pain mechanisms, and the pharmacology of analgesics.

Pain in gynecologic cancer may be the result of soft tissue infiltration, bone involvement, neural involvement, muscle spasm (e.g., psoas spasm), infection within or near tumor masses, or bowel colic.

Therapeutic approaches vary according to the pain mechanism involved. Consideration must be given to the specific therapeutic measure that may be appropriate in the individual case, such as radiation therapy, chemotherapy, antibiotics, regional nerve block, or surgery.

Peripherally acting drugs such as acetaminophen (paracetamol) should rarely be omitted from analgesic regimes, and rectal suppositories are useful if oral intake is not appropriate. When pain is caused by bone metastases, nonsteroidal antiinflammatory drugs or bisphosphonates are helpful. Muscle spasm requires muscle relaxants such as diazepam, whereas bowel colic requires anticholinergics such as busulfan.

Opioid use will be necessary for severe pain, although nerve pain and muscle spasm are not well relieved by opioids. A variety of opioids are available, and in general, a low-potency opioid such as codeine or a high-potency opioid such as morphine is combined with a peripherally acting drug such as acetaminophen or aspirin.

Immediate-release morphine, which is best given orally or subcutaneously, should be given at regular 4-hour intervals. Controlled-release morphine tablets are a significant advance in convenience of administration because they need to be given only every 12 to 24 hours, once the total 24-hour requirement has been determined from the use of an immediate-release preparation. Constipation is a real problem with opioids, and prophylactic laxatives should be prescribed.

Alternative opioids (with equivalency to morphine 5 mg) include oxycodone (5 mg), hydromorphone (1 mg), pentazocine (45 mg), and meperidine (75 mg).

When pain is neurogenic in origin, an opioid and a peripherally acting drug should usually be supplemented by a tricyclic antidepressant, an anticonvulsant, or a corticosteroid.